Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
- Conditions
- Leukemia
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- German CLL Study Group
- Registration Number
- NCT00274976
- Locations
- 🇩🇪
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany
🇩🇪Haematolo-Onkologische Schwerpunktpraxis - Berlin, Berlin, Germany
🇩🇪Specialist Practice for Oncology, Aschaffenburg, Germany
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 60
- Registration Number
- NCT00274963
- Locations
- 🇩🇪
Schwerpunktpraxis fuer Haematologie und Internistische Onkologie, Berlin, Germany
🇩🇪Internistische Gemeinschaftspraxis - Halle, Halle, Germany
🇩🇪Internistische Praxis - Neuss, Neuss, Germany
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biological: Rituximab
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 195
- Registration Number
- NCT00274989
- Locations
- 🇩🇪
HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Internistische Praxis - Arnstadt, Arnstadt, Germany
🇩🇪Klinikum Augsburg, Augsburg, Germany
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 825
- Registration Number
- NCT00275054
- Locations
- 🇦🇹
Universitaetsklinik fuer Innere Medizin I, Vienna, Austria
🇫🇷CHU Poitiers, Poitiers, France
🇩🇪St. Hedwig Krankenhaus, Berlin, Germany
Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 877
- Registration Number
- NCT00262782
- Locations
- 🇩🇪
Internistische Praxis - Neuenkirchen, Neuenkirchen, Germany
🇩🇪Klinikum St. Marien, Amberg, Germany
🇩🇪Internistische Praxis - Arnstadt, Arnstadt, Germany
Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 206
- Registration Number
- NCT00262795
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis, Cottbus, Germany
🇦🇹Hanuschkrankenhaus, Vienna, Austria
🇩🇪Saint Josef - Hospital Bochum, Bochum, Germany
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
- Conditions
- B-cell Chronic Lymphocytic Leukemia
- Interventions
- Drug: FCCam
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 61
- Registration Number
- NCT00147901
- Locations
- 🇩🇪
University of Cologne, Cologne, NRW, Germany